Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Natalie H. Surh"'
Autor:
Erik Van Dis, Kimberly M. Sogi, Chris S. Rae, Kelsey E. Sivick, Natalie H. Surh, Meredith L. Leong, David B. Kanne, Ken Metchette, Justin J. Leong, Jacob R. Bruml, Vivian Chen, Kartoosh Heydari, Nathalie Cadieux, Tom Evans, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Daniel A. Portnoy, Sarah A. Stanley
Publikováno v:
Cell Reports, Vol 23, Iss 5, Pp 1435-1447 (2018)
Summary: There are a limited number of adjuvants that elicit effective cell-based immunity required for protection against intracellular bacterial pathogens. Here, we report that STING-activating cyclic dinucleotides (CDNs) formulated in a protein su
Externí odkaz:
https://doaj.org/article/5af82e8c90b24ca6bea46b4f64e9ab0e
Autor:
Kelsey E. Sivick, Anthony L. Desbien, Laura Hix Glickman, Gabrielle L. Reiner, Leticia Corrales, Natalie H. Surh, Thomas E. Hudson, Uyen T. Vu, Brian J. Francica, Tamara Banda, George E. Katibah, David B. Kanne, Justin J. Leong, Ken Metchette, Jacob R. Bruml, Chudi O. Ndubaku, Jeffrey M. McKenna, Yan Feng, Lianxing Zheng, Steven L. Bender, Charles Y. Cho, Meredith L. Leong, Andrea van Elsas, Thomas W. Dubensky, Jr., Sarah M. McWhirter
Publikováno v:
Cell Reports, Vol 25, Iss 11, Pp 3074-3085.e5 (2018)
Summary: Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet factors dictating the balance between innate and adaptive anti-tumor immunity are unclear. Here, clinical candidate STING agonist ADU-S100 (S100) is us
Externí odkaz:
https://doaj.org/article/6640eed869a2425eb7c9442fb0d88d76
Autor:
Chris S. Rae, Natalie H. Surh, Kimberly M. Sogi, Meredith L. Leong, Daniel A. Portnoy, Ken Metchette, Nathalie Cadieux, Sarah M. McWhirter, Vivian Chen, Erik Van Dis, David B. Kanne, Kartoosh Heydari, Justin Leong, Thomas G. Evans, Jacob Robert Bruml, Thomas W. Dubensky, Kelsey E. Sivick, Sarah A. Stanley
Publikováno v:
Cell reports, vol 23, iss 5
Cell Reports, Vol 23, Iss 5, Pp 1435-1447 (2018)
Cell Reports, Vol 23, Iss 5, Pp 1435-1447 (2018)
Summary: There are a limited number of adjuvants that elicit effective cell-based immunity required for protection against intracellular bacterial pathogens. Here, we report that STING-activating cyclic dinucleotides (CDNs) formulated in a protein su
Autor:
George E. Katibah, Sarah M. McWhirter, Kelsey E. Sivick, Natalie H. Surh, Eric P. Grewal, Thomas W. Dubensky, Anthony L. Desbien
Publikováno v:
The Journal of Immunology. 198:4183-4185
STING is a signaling protein encoded by the human TMEM173 gene that is central to the host response to infection. Upon binding cyclic dinucleotides (CDNs), STING activates transcriptional programs that orchestrate innate and adaptive immune responses
Autor:
Meredith L. Leong, Weiwen Deng, Chudi Ndubaku, Sarah M. McWhirter, Lianxing Zheng, Ken Metchette, Kelsey Sivick Gauthier, Jeffery M. McKenna, Laura Hix Glickman, Charles Y. Cho, Tamara Schroeder, Anthony L. Desbien, Natalie H. Surh, Andrea van Elsas, Bender Steven Lee, Yan Feng, Leticia Corrales, Justin Leong, Brian Francica, Gabrielle L. Reiner
Publikováno v:
Cancer Immunology Research. 8:PR09-PR09
Stimulator of interferon genes (STING) is a critical component of an innate immune pathway that activates robust antiviral and antitumor responses in mouse models. Activation of the STING pathway by intratumoral (IT) injection of synthetic cyclic din
Autor:
Thomas E. Hudson, George E. Katibah, Gabrielle L. Reiner, Leticia Corrales, David B. Kanne, Lianxing Zheng, Anthony L. Desbien, Thomas W. Dubensky, Jacob Robert Bruml, Chudi Ndubaku, Yan Feng, Meredith L. Leong, Ken Metchette, Justin Leong, Natalie H. Surh, Andrea van Elsas, Uyen T. Vu, Bender Steven Lee, Tamara Banda, Sarah M. McWhirter, Laura Hix Glickman, Charles Y. Cho, Jeffrey Mckenna, Brian Francica, Kelsey E. Sivick
Publikováno v:
Cell Reports, Vol 25, Iss 11, Pp 3074-3085.e5 (2018)
Summary: Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet factors dictating the balance between innate and adaptive anti-tumor immunity are unclear. Here, clinical candidate STING agonist ADU-S100 (S100) is us
Autor:
Weiwen Deng, Jeffery M. McKenna, George E. Katibah, Andrea van Elsas, Ken Metchette, Bender Steven Lee, Thomas W. Dubensky, Thomas E. Hudson, Uyen T. Vu, Kelsey Sivick Gauthier, Meredith L. Leong, Sarah M. McWhirter, Leticia Corrales, Laura Hix Glickman, Gabrielle L. Reiner, Brian Francica, Justin Leong, David B. Kanne, Anthony L. Desbien, Chudi Ndubaku, Natalie H. Surh
Publikováno v:
Cancer Research. 78:631-631
Activation of the STING pathway by intratumoral (IT) injection of synthetic cyclic dinucleotides (CDNs) induces stable tumor regression in preclinical models, yet the underlying immune correlates are not fully understood. ADU-S100, a CDN under clinic